Lupin acquires diabetes brands ONDERO and ONDERO MET from Boehringer Ingelheim
In a strategic move to fortify its position in the pharmaceutical domain, global major Lupin Limited proclaimed its acquisition of coveted diabetes brands ONDERO and ONDERO MET from Boehringer Ingelheim International GmbH. These brands, which Lupin has been marketing since 2015 under a co-marketing arrangement, come with the added bonus of trademark rights. India grapples […]